Global Immunology Market Size study & Forecast, by Drug Class (Monoclonal Antibody, Immunosuppressants, Fusion Proteins, Others) by Disease Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel

Global Immunology Market Size study & Forecast, by Drug Class (Monoclonal Antibody, Immunosuppressants, Fusion Proteins, Others) by Disease Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Regional Analysis, 2022-2029

Global Immunology Market is valued at approximately USD 97.93 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 8.5% over the forecast period 2022-2029. Immunology is the field of medical and biological research that focuses and studies the immune system. The immune system protects individuals from infection in numerous ways. by enhancing or inhibiting the immune system, immunology medications and substances alter the immunological response. Immunology drugs or agents are used to treat or prevent infections as well as several autoimmune and immunological diseases such type 1 diabetes, rheumatoid arthritis, and psoriatic arthritis. The global market growth is primarily driven by the factors such as a surge in demand for biosimilars, growing awareness about immunological diseases, coupled with the increasing demand for preventive care.

In addition, the rise in incidences of autoimmune disorders is a key factor that is stipulating the market demand in the global market. A study by the National Stem Cell Foundation estimates that at least one of 80 or more autoimmune illnesses affects about 4% of people around the world. For instance, various market participants are focusing on creating and introducing new products to the market as a result of the growing demand for these medications among patients. For instance, Lupin introduced a generic rheumatoid arthritis medication in September 2020. Likewise, As of April 2022, there were approximately 20 pipeline projects from Johnson & Johnson Services, Inc. for a variety of autoimmune indications, including psoriatic arthritis, rheumatoid arthritis, inflammatory bowel disease, and others, and approximately 30 pipeline projects from Sanofi in the immunology segment. Thereby, the increasing prevalence of autoimmune disorders and growing emphasis on introducing its treatments is boosting the market growth. Moreover, the rising introduction of novel therapies, as well as the increasing product approvals by regulatory agencies are presenting various lucrative opportunities over the forecasting years. However, the high cost of treatment and adverse effects associated with the product are hampering the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Immunology Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the availability of advanced healthcare infrastructure, along with growing investment on research and development activities. Whereas, the Asia Pacific is also expected to grow with the highest CAGR during the forecast period, owing to factors such as rising occurrence of autoimmune conditions, surging demand for preventive care, and increasing drug approvals in the regional market space.

Major market players included in this report are:
AbbVie, Inc.
Janssen Global Services, LLC
Eli Lilly and Company
Novartis AG
Pfizer Inc.
Bristol-Myers Squibb Company
Merck Sharp & Dohme Corp.
F. Hoffmann-La Roche Ltd.
Amgen Inc.
Astellas Pharma Inc.

Recent Developments in the Market:
In June 2022, Eli Lilly and Company received the U.S. FDA approval for its OLUMIANT- a first-in-disease systemic treatment that is specially developed for adults with severe alopecia areata (AA), an autoimmune disorder.
In April 2022, AbbVie Inc. received the U.S. FDA approval for its RINVOQ to provide treatment to adult patients with active ankylosing spondylitis.
In March 2022, Pfizer Inc. announced that the company acquired Arena Pharmaceuticals, a company that primarily focuses on advancing innovative potential therapies to cure several immuno-inflammatory diseases. The objective of this acquisition is to expand Pfizer Inc. product portfolio.

Global Immunology Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Drug Class, Disease Indication, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Drug Class:
Monoclonal Antibody
Immunosuppressants
Fusion Proteins
Others
By Disease Indication:
Rheumatoid Arthritis
Psoriatic Arthritis
Plaque Psoriasis
Ankylosing Spondylitis
Inflammatory Bowel Disease
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned
AbbVie, Inc.
Janssen Global Services, LLC
Eli Lilly and Company
Novartis AG
Pfizer Inc.
Bristol-Myers Squibb Company
Merck Sharp & Dohme Corp.
F. Hoffmann-La Roche Ltd.
Amgen Inc.
Astellas Pharma Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.